SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility as the community remains deeply divided between those betting on a sustained rally fueled by upcoming global events and critics who are labeling the project a textbook pump-and-dump scheme due to its highly concentrated token ownership. Investors are actively debating the legitimacy of the rapid price spike, with many drawing comparisons to previous high-profile crypto collapses while others rush to find the next short-term opportunity.

Asteroid Shiba is inspired by a real-life event where a Shiba Inu plush toy named "Asteroid" served as a zero-gravity indicator during the Polaris Dawn mission. This connection to space travel gives it a narrative that's both whimsical and grounded in a tangible event, differentiating it from other meme coins which might rely solely on internet culture or celebrity endorsements.  The coin's mascot, the zero-gravity Shiba Inu, was designed by a young cancer survivor, Liv Perrotto, adding a layer of emotional connection and human interest story that's rare in the crypto space. This backstory not only provides a unique selling point but also a community rallying point.

Asteroid Shiba

Asteroid Shiba is attracting significant speculative attention due to rapid price volatility and community chatter surrounding its potential as a new sector meta. Investors are actively debating the sustainability of this momentum while drawing comparisons to other high-profile meme tokens and broader market trends.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is currently drawing investor attention as it faces conflicting market signals, with analysts weighing promising long-term growth in AI-powered edge computing and automotive sectors against immediate concerns over smartphone demand and memory supply chain constraints. Shareholders are actively debating these fundamentals, particularly following recent dividend increases and major share buyback announcements, while monitoring for potential catalysts related to future data center and AR hardware partnerships.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is trending as investors debate its long-term potential as a DeFi leader, with the community actively comparing its valuation metrics and tokenomics to competitors like Compound. Sentiment remains divided, with supporters highlighting upcoming protocol upgrades and institutional adoption as key catalysts, while skeptics point to historical volatility and governance concerns.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending as a standout performer, fueled by a strong Q3 earnings beat that showcased double-digit growth in global procedure volumes and successful adoption of its next-gen robotic systems. Investors and the community are closely monitoring this momentum, debating whether the companys durable business model can justify its current valuation amidst ongoing sector volatility and competitive market pressures.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is surging due to investor enthusiasm surrounding an executive order aimed at fast-tracking research into ibogaine and other psychedelics for treating PTSD in veterans. The community is actively debating the stock's potential for a significant short squeeze given its low float and heavy short interest, though some warn of the risks associated with the high volatility and potential for profit-taking following recent gains.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is currently experiencing heightened community engagement as investors discuss the potential for a long-term recovery, fueled by ongoing token burn initiatives and speculation surrounding exchange relisting news. Market participants remain divided, with a vocal base of long-term supporters focused on ecosystem development and price appreciation, while others remain skeptical given the project's historical volatility.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently in the spotlight as investors digest its aggressive strategic pivot toward selling in-house CPUs for data centers and AI workloads, a move expected to significantly expand its revenue potential. While the community is actively debating the stock's valuation versus its growth prospects, strong institutional interest and partnerships with major hyperscalers are keeping the ticker a focal point for momentum traders.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to a significant policy catalyst after President Trump signed an executive order to fast-track FDA reviews for psychedelic-assisted therapies, potentially accelerating the clinical development paths for assets like DT120. While the community is debating the stock's future amid historical dilution concerns and management scrutiny, many are actively monitoring for volume expansion and potential institutional re-rating as the broader psychedelic sector faces a pivotal year of trial readouts.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is currently trending due to its strategic role as a domestic leader in the U.S. rare earth supply chain, heavily supported by government initiatives and partnerships aimed at reducing reliance on China. The community is actively discussing its long-term potential, with debates centered on the company's path to full vertical integration, its defense-sector backing, and the ongoing market volatility impacting the entire rare earth and critical minerals mining space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Short Interest Update

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 771,223...

Apella Capital LLC Buys New Position in Alpha Tau Medical Ltd. $DRTS

Apella Capital LLC bought a new stake in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange...

Alpha Tau Medical (NASDAQ:DRTS) Shares Up 5.2%  - Here's What Happened

Alpha Tau Medical (NASDAQ:DRTS) Shares Up 5.2% - Still a Buy...

Daytona Street Capital LLC Invests $749,000 in Alpha Tau Medical Ltd. $DRTS

Daytona Street Capital LLC purchased a new position in shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F...

<ul class="summary-bullets"><li>Alpha Tau’s IMPACT trial is expected to enroll up to 30 patients across the U.S., Canada, and Israel, focusing on patients with newly diagnosed, inoperable pancreatic adenocarcinoma.</li><li>The ReSTART study is to evaluate Alpha DaRT in patients with recurrent cutaneous squamous cell carcinoma, a common form of skin cancer.</li><li>Patient enrollment for both trials is expected to be completed by the end of the first quarter of 2026.</li></ul>Alpha Tau Medical (DRTS) drew strong retail attention on Monday as the oncology therapeutics firm approaches a key catalyst, with markets awaiting crucial patient enrolment data in pancreatic cancer and cutaneous squamous cell carcinoma (cSCC) trials.<a href="https://stocktwits.com/symbol/DRTS">DRTS shares</a> were down 4% in pre-market trading at the time of writing.<h2 class="st-heading-2">IMPACT Study For Pancreatic Cancer</h2>Alpha Tau’s IMPACT trial is expected to enroll up to 30 patients across the U.S., Canada, and Israel, focusing on those with newly diagnosed, inoperable pancreatic adenocarcinoma. Patient enrollment is expected to be completed by the end of the first quarter of 2026.Participants will continue standard chemotherapy while receiving the company’s Alpha DaRT, a targeted radiation therapy delivered directly into tumors using ultrasound-guided endoscopy.The study aims to evaluate the safety, feasibility, and effectiveness of the treatment, while also tracking tumor response and survival outcomes. Researchers will additionally assess whether some patients with locally advanced disease become eligible for surgery after treatment, a key potential benefit of the therapy, the company said.<h2 class="st-heading-2">ReSTART Trial Targets Skin Cancer Opportunity</h2>Alpha Tau is currently running its multi-center ReSTART study to evaluate Alpha DaRT in patients with recurrent cutaneous squamous cell carcinoma (cSCC), a common form of skin cancer. Patient enrollment is expected to be completed in the first quarter of 2026.The trial supports the use of Alpha DaRT, particularly for patients who are not eligible for surgery or standard radiation.The company has already secured Breakthrough Device Designation from the U.S. Food and Drug Administration for this indication, as well as for recurrent glioblastoma multiforme, a type of brain tumor, and oral cavity cancers.This designation reflects the regulator’s view that the therapy could offer significant advantages over existing treatments and allows for an accelerated review and development pathway. It is also part of the FDA’s Total Product Life Cycle Advisory Program.<h2 class="st-heading-2">DRTS Stock: Retail Sentiment Signals High Expectations&nbsp;</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, accompanied by ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/DRTS_jpg_933216b5d9.webp" alt="DRTS.jpg">Chatter was largely bullish, with one user stating that the company’s current market value could look very low in hindsight if there are further positive updates from the ReSTART trial.<stembedurl>https://stocktwits.com/Joshsim123/message/648904774</stembedurl>Another user said the stock’s current value feels like a “massive mispricing.”<stembedurl>https://stocktwits.com/Jessypenny/message/648902299</stembedurl>Year-to-date, the stock has gained nearly 38%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/soc-stock-gains-california-pipeline-restart-sales/cZERVWqRIZt">Sable Offshore Begins Oil Sales From Highly Scrutinized California Pipeline – SOC Stock Gains 3% Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

DRTS Stock Is Back On Retail Radar Ahead Of High-Stakes Cancer Trial Updates

The market is awaiting the company’s patient enrolment data from pancreatic cancer and cutaneous squamous cell carcinoma trials, a key factor in advancing the studies.

Why Alpha Tau Is Back On Traders’ Radar? 

Equity

Alpha Tau Medical Ltd. (NASDAQ:DRTS) Given Average Recommendation of "Hold" by Brokerages

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) has received a consensus rating of "Hold" from the five brokerages that are covering the firm, Marketbeat Ratings reports. One equities research...

Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up   - Here's Why

Alpha Tau Medical (NASDAQ:DRTS) Shares Gap Up - Here's What Happened...

Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts Teased

Alpha Tau Medical (NASDAQ:DRTS) provided investors with a series of clinical, regulatory and financial updates, highlighting what company leadership described as real and meaningful activity over the...

HC Wainwright Issues Pessimistic Estimate for DRTS Earnings

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) - Investment analysts at HC Wainwright cut their Q1 2026 EPS estimates for shares of Alpha Tau Medical in a research report issued on Tuesday, March...

Citigroup Increases Alpha Tau Medical (NASDAQ:DRTS) Price Target to $9.00

Citigroup boosted their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday...

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

DRTS
ALPHA TAU MEDICAL LTD

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DRTS News

DRTSALPHA TAU MEDICAL LTD